E2F2 and breast carcinoma: The analyses concerned with types of cancer, such as breast cancer, ovarian cancer, colon cancer, gastric cancer, prostate cancer, hepatocellular carcinoma, non-small cell lung cancer cell, glioma, and laryngeal cancer, suggested that miRNAs, by targeting E2F2, could be involved in cancer progression, overall survival of patients, and response to radiochemotherapy [37,38,39,40,41,42,43,44,45,46].